Scientists find clue to lower dementia risk in older adults through new ‘game-changer’ vaccine
Large-scale health record analysis shows new Shingrix vaccine linked to 24% lower dementia risk in older adults
Affecting tens of millions of individuals globally—predominantly older adults, dementia represents a major public health challenge for the vulnerable.
Medical experts reveal, the condition places significant emotional, physical, and financial burdens on patients, families, and healthcare infrastructure.
Early signs typically involve memory loss, difficulty with problem-solving, and confusion with time or place.
As the disease progresses, individuals may experience personality changes, communication difficulties, and a complete reliance on round-the-clock care.
A large-scale study of vulnerable older adults reveals that receiving the modern Shingrix shingles vaccine is associated with a substantial reduction in the risk of a dementia diagnosis over a four-year period.
While evaluating the outcome, researchers tracked over more than 500,000 older adults reveals that the recombinant shingles vaccine called "Shingrix" is associated with a 24% lower risk of a dementia diagnosis over a four-year period.
They compared patients who received at least one dose of the recombinant shingles vaccine, known as RZV or Shingrix, with patients who remained unvaccinated.
As reported by ScienceDaily, a group of researchers analyzed medicare claims and electronic health records for patients admitted to skilled nursing facilities between 2017 and 2022, creating a real-world evaluation window for a high-risk demographic.
The results revealed, over the four-year follow-up, dementia developed in 18.8% of vaccinated participants, compared to 24.6% of those who remained unvaccinated.
Investigators estimate, this difference translates to roughly one dementia case prevented for every 17 people vaccinated.
While the observational data cannot definitively prove direct cause-and-effect, researchers believe the findings align with a growing body of evidence.
Potential mechanisms include preventing the systemic inflammation and vascular complications tied to herpes zoster flare-ups, or broader immune-boosting neuroprotective effects.
Scientists emphasize that while confounding lifestyle factors were adjusted for, randomized clinical trials will be necessary to fully establish whether the vaccine directly preserves cognitive function.
The research materials for the study 'Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay' was provided by Brown University and the search was published in the JournalAnnals of Internal Medicine, 2026.
